Physician profile
Michael E Garrison
NPI 1003869447
$1,039.78
in general payments reported to CMS, 2019-2025
23 companies · $318 in 2025
The $318 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $62.84 · 2021: $11.92 · 2022: $86.87 · 2023: $227 · 2024: $121 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $665.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $322.53 | 2019-2024 | Opdivo, Eliquis |
| Janssen Biotech, INC. | $110.90 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $58.39 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Celgene Corporation | $56.61 | 2022-2023 | Reblozyl |
| Genzyme Corporation | $50.38 | 2024 | |
| Novartis Pharmaceuticals Corporation | $49.38 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $47.68 | 2023-2025 | Orgovyx |
| Glaxosmithkline, LLC. | $41.48 | 2023 | Zejula |
| Daiichi Sankyo INC. | $37.94 | 2024-2025 | Vanflyta |
| Astellas Pharma US INC | $31.34 | 2025 | Cresemba |
| Recordati_rare_diseases_inc. | $28.10 | 2025 | Enjaymo |
| Geron Corporation | $25.48 | 2025 | Rytelo |
| Incyte Corporation | $24.99 | 2025 | Jakafi |
| Cti Biopharma Corp. | $24.30 | 2023 | Vonjo |
| Bayer Healthcare Pharmaceuticals INC. | $22.62 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $22.23 | 2025 | Brukinsa |
| Genentech USA, INC. | $21.65 | 2025 | Venclexta |
| Sobi, INC | $18.22 | 2025 | |
| Taiho Oncology, INC. | $18.08 | 2025 | |
| Beigene USA, INC. | $15.56 | 2024 | Brukinsa |
| Gilead Sciences, INC. | $11.92 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Garrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.